Basilea Pharmaceutica AG (OTCMKTS:BPMUF) Short Interest Update

Basilea Pharmaceutica AG (OTCMKTS:BPMUF) was the recipient of a significant decrease in short interest in February. As of February 28th, there was short interest totalling 15,700 shares, a decrease of 29.0% from the February 13th total of 22,100 shares. Currently, 0.1% of the shares of the company are sold short. Based on an average daily trading volume, of 0 shares, the short-interest ratio is presently ∞ days.

Basilea Pharmaceutica Price Performance

OTCMKTS:BPMUF opened at $52.83 on Monday. The company has a debt-to-equity ratio of 5.70, a quick ratio of 3.27 and a current ratio of 4.10. Basilea Pharmaceutica has a 52 week low of $38.60 and a 52 week high of $52.83. The stock’s 50-day moving average price is $52.83 and its 200-day moving average price is $52.49.

Basilea Pharmaceutica Company Profile

Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union.